New Two-Drug attack on mysterious cancers
NCT ID NCT06754501
Summary
This study is testing whether a combination of two immunotherapy drugs, atezolizumab and tiragolumab, can help control cancer of unknown primary (CUP), a type of cancer where the original site is unknown. It is for adults with advanced CUP who have already tried or cannot have standard chemotherapy. The main goals are to see if the treatment shrinks tumors and is safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.